The Cigna GroupCI
Recorded

The Cigna Group 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 4 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Ladies and gentlemen, thank you for standing by for The Cigna Group's third quarter 2026 results review. At this time, all callers are in a listen-only mode. We will conduct a question-and-answer session later during the conference and review procedures on how to enter queue to ask questions at that time. If you should require assistance during the call, please press star 0 on your touch-tone phone. As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded. We will begin by turning the conference over to Ralph Giacobbe. Please go ahead. Great, thanks.

Ralph GiacobbeSVP of Investor Relations

Good morning. Thank you for joining today's call. I am Ralph Giacobbe, Senior Vice President of Investor Relations. With me on the line this morning are Brian Evanko, The Cigna Group's President and Chief Executive Officer, and Ann Dennison, Chief Financial Officer. In our remarks today, Brian and Ann will cover a number of topics, including our third quarter 2026 financial results and our financial outlook for 2026. Following their prepared remarks, Brian and Ann will be available for Q&A. As noted in our earnings release, when describing our financial results, we use certain financial measures, including adjusted income from operations and adjusted revenues, which are not determined in accordance with accounting principles generally accepted in the U.S., otherwise known as GAAP.

Ralph GiacobbeSVP of Investor Relations

A reconciliation of these measures to the most directly comparable GAAP measures, shareholders' net income and total revenues respectively, is contained in today's earnings release, which is posted in the Investor Relations section of thecignagroup.com. We use the term labeled adjusted income from operations and adjusted earnings per share on the same basis as our principal measures of financial performance. In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2026 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. Regarding our results in the third quarter, we recorded after-tax special item charges of $146 million, or $0.55 per share.

Ralph GiacobbeSVP of Investor Relations

Details of the special items are included in our quarterly financial supplement. Additionally, please note that when we make prospective comments regarding financial performance, including our full year 2026 outlook, we will do so on a basis that includes the potential impact of future share repurchases and anticipated 2026 dividends. With that, I will turn the call over to Brian.

Brian EvankoPresident and CEO

Thanks, Ralph. Good morning, everyone, and thank you for joining our call. I am pleased to share that The Cigna Group delivered strong performance in the third quarter as we continue executing on our strategy. Today, I will cover our results for the quarter and key drivers, our profitable growth strategy, and how we are advancing toward our long-term EPS growth algorithm of 10%-14%, which we laid out at our recent investor day, as well as how our strategic growth framework positions us to build momentum in 2027. Then Ann will share additional details about our financial results and outlook for the rest of the year, and we will take your questions. During the quarter, we delivered adjusted revenue of $73.8 billion, adjusted after-tax earnings of $2.1 billion, and adjusted earnings per share of $7.98.

Brian EvankoPresident and CEO

The work we have done over several years to deliberately shape our portfolio is delivering results, and we are built for the fastest-growing areas of healthcare with a proven ability to execute through a dynamic environment. Our strong performance through the first nine months of the year gives us confidence to raise our full-year outlook, and we now expect adjusted earnings per share of at least $30.60. Importantly, we are building on that strong foundation as we look beyond 2026. At our recent investor day, we announced our Lead to One vision, which is centered on delivering personalization at scale to improve affordability and the healthcare experience for every customer and patient we serve. Lead to One brings together all of our medical, pharmacy, behavioral health, and specialty care capabilities around the individual.

Brian EvankoPresident and CEO

By responsibly leveraging our data, clinical expertise, and technology, we can identify needs earlier, deliver more personalized support, and improve health outcomes while lowering the total cost of care. Our Lead to One vision will benefit all customers, and we see a particular opportunity with the most clinically complex patient needs, where healthcare costs are increasingly concentrated and represent over 50% of total healthcare spending. Lead to One is underpinned by a clear strategic growth framework comprised of three pillars. First, we will deliver core growth. Second, we will leverage distinct capabilities. Third, we will execute with discipline. These three pillars taken together give us a clear path to build on the strength of our business today while creating the next chapter of sustainable growth and greater value for those we serve.

Brian EvankoPresident and CEO

Now let me walk through some of our highlights in the quarter across Evernorth Health Services and Cigna Healthcare. Starting in Evernorth, third quarter earnings were in line with expectations. Our specialty and care services businesses delivered attractive performance, including pre-tax adjusted earnings growth of 15% year-over-year. This was fueled by secular tailwinds and disciplined execution across our specialty pharmacy and distribution capabilities. We also drove continued strong biosimilar and specialty generic utilization. Today, Revlimid, a widely used oncology drug, is seeing specialty generic adoption rates around 90%. Across our specialty businesses, we are leveraging our distinct capabilities for patients with complex needs who require a higher level of care, support, and coordination to manage their conditions. For example, in our specialty pharmacy, Accredo, we have industry-leading access with more than 330 highly complex, limited distribution, and exclusive products.

Brian EvankoPresident and CEO

This demonstrates the strength of our manufacturer relationships and the trust they place in us to partner in serving some of the most clinically complex patient needs. That access also positions us to capture growth as new specialty therapies come to market. I am also pleased to share that we continue to expand our capacity for these limited distribution products with our network of clean rooms, the fifth of which is now in the build phase. These highly sterile environments take years to build, license, and operationalize to safely mix and compound some of the most complex medicines. These clean rooms are just one example of the durable competitive advantage in our specialty business that we have constructed over the past few decades. Finally, our expanded distribution channels are unlocking new opportunities. CuraScript SD is a leader in specialty distribution with access to 40 exclusive distribution drugs.

Brian EvankoPresident and CEO

Our recently launched Evernorth Wholesale has begun fulfilling orders to our distribution centers to be able to serve customers. In our Pharmacy Benefit Services business in Evernorth, we delivered third quarter pre-tax adjusted earnings of $765 million. We continue to see strong momentum for the 2027 sales season, supporting our core growth, along with strong retention rates in the high 90s. Next, I would like to spend a moment on our Signature model transition. We are pioneering this new approach to pharmacy benefits and want you to have further context around current status and why we are so confident in our path. You can think of our Signature implementation in three broad phases. Phase one, our design phase, is complete. Announced this time last year, phase one included designing Signature, our market-defining innovation, driven by core principles of affordability, simplicity, transparency, and value.

Brian EvankoPresident and CEO

Inherent in the model is our price assure capability, which is designed to ensure patients pay the lowest available out-of-pocket costs when they fill prescriptions, and will save an average of 30% on high-cost branded drugs. price assure is already in market and being leveraged by about 10% of our current clients. The Signature model is consistent with the direction of regulatory changes, including the Consolidated Appropriations Act of 2026 and the Department of Labor's recently finalized PBM fee disclosure rule. Phase two, our build phase, is well underway. Currently, we are working on adoption planning alongside market education. Key stakeholders include brokers, pharmaceutical manufacturers, network pharmacy partners, and clients. The work is largely complete for brokers, and we are actively advancing contracts with pharmaceutical manufacturers and network pharmacies. Phase three, our adoption phase, is on track.

Brian EvankoPresident and CEO

The next milestone is the adoption of Signature for our Cigna Healthcare fully insured book on 1/1/2027. Early client conversations for the 2028 benefits year have been encouraging and indicate strong interest in the model for a broader Evernorth book of Pharmacy Benefit Services clients. Our very strong 2027 selling season reinforces that clients value innovation and see us as a multi-year partner on their pharmacy benefits journey. Clients see value in Signature's focus on patient affordability and transparency, and in how it supports their efforts to meet evolving regulatory requirements and their fiduciary responsibilities. They also see a model that can encourage adherence with improved health outcomes and workforce productivity. In summary, we are proud of the progress we are making on Signature. We have completed phase one and are on track to deliver against phases two and three, with broader client adoption expected to ramp in 2028.

Brian EvankoPresident and CEO

We'll share some further detail on the progress across phases II and III during our fourth quarter earnings call. Finally, we continue to leverage our distinct capabilities in Pharmacy Benefit Services to generate industry-leading affordability outcomes, including our deep supply chain expertise, clinical safety checks, and connectivity in the rapidly evolving pharmaceutical market to meet the needs of clients and customers. We're continuing to enhance our technology platforms, better connecting the different components of the pharmacy benefit to create a simpler, more flexible experience for patients and clients. Turning to Cigna Healthcare, we delivered another quarter of strong growth with results ahead of expectations, with pre-tax adjusted earnings growth of 15% year-over-year. Our disciplined pricing, coupled with advanced analytics and insights, enable our steady medical care ratio performance. While medical cost trends continue to be elevated, they are consistent with our expectations and pricing assumptions.

Brian EvankoPresident and CEO

This quarter, we also benefited from stronger net investment income and favorable SG&A performance. We also introduced new capabilities in Cigna Healthcare in September with the launch of Health Sense, our data and technology-powered customer engagement solution that will start with oncology, but broaden to other conditions over time. By connecting a customer's health needs, benefits, pharmacy coverage, costs, claims, and prior interactions, our clinical teams have context and a more complete picture, enabling earlier interventions. As a reminder, costs are increasingly concentrated in complex conditions, with 8% of patients generating 55% of total healthcare spend. We're excited about the early positive reception to Health Sense from clients and customers, and are taking an agile approach to launching additional components as they are built. As we look to 2027, we remain confident in the strength of our strategic growth framework and our ability to perform through a dynamic environment.

Brian EvankoPresident and CEO

During our fourth quarter call, we will provide our comprehensive 2027 guidance. We continue to expect adjusted earnings per share growth of at least 10% in 2027 off our run rate earnings for our ongoing businesses, and remain confident in 2030 adjusted earnings per share of at least $45 that we outlined at our Investor Day. Today, I'll briefly cover the primary tailwinds and headwinds for 2027. Starting with the tailwinds. First, in our Cigna Healthcare business, we are driving continued improvement in our stop-loss margins. Second, we're pleased with a strong 2027 selling season in both Evernorth and Cigna Healthcare. High client retention and new business wins reinforce the strength of our value proposition and innovation, and will contribute to attractive enterprise revenue growth in 2027. Third, our Accelerate to One modernization and productivity initiative will drive savings across the enterprise.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day